Agios Pharmaceuticals (AGIO) Revenue & Revenue Breakdown
Agios Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$26.82M
Latest Revenue (Q)
$8.62M
Main Segment (Y)
Product
Agios Pharmaceuticals Revenue by Period
Agios Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $26.82M | 88.36% |
| 2022-12-31 | $14.24M | 100.00% |
| 2021-12-31 | - | -100.00% |
| 2020-12-31 | $203.20M | 72.33% |
| 2019-12-31 | $117.91M | 24.92% |
| 2018-12-31 | $94.39M | 119.45% |
| 2017-12-31 | $43.01M | -38.46% |
| 2016-12-31 | $69.89M | 18.22% |
| 2015-12-31 | $59.12M | -9.55% |
| 2014-12-31 | $65.36M | 155.82% |
| 2013-12-31 | $25.55M | 1.76% |
| 2012-12-31 | $25.11M | 14.97% |
| 2011-12-31 | $21.84M | - |
Agios Pharmaceuticals generated $26.82M in revenue during NA 2023, up 88.36% compared to the previous quarter, and up 28.42% compared to the same period a year ago.
Agios Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $8.62M | 5.20% |
| 2024-03-31 | $8.19M | 15.29% |
| 2023-12-31 | $7.10M | -4.00% |
| 2023-09-30 | $7.40M | 10.24% |
| 2023-06-30 | $6.71M | 19.66% |
| 2023-03-31 | $5.61M | 30.14% |
| 2022-12-31 | $4.31M | 22.58% |
| 2022-09-30 | $3.52M | -37.01% |
| 2022-06-30 | $5.58M | 570.91% |
| 2022-03-31 | $832.00K | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | -100.00% |
| 2021-06-30 | $37.35M | -9.81% |
| 2021-03-31 | $41.41M | -5.98% |
| 2020-12-31 | $44.05M | 26.91% |
| 2020-09-30 | $34.71M | -7.07% |
| 2020-06-30 | $37.35M | -57.12% |
| 2020-03-31 | $87.10M | 145.76% |
| 2019-12-31 | $35.44M | 36.18% |
| 2019-09-30 | $26.02M | -0.75% |
| 2019-06-30 | $26.22M | -13.25% |
| 2019-03-31 | $30.23M | 0.71% |
| 2018-12-31 | $30.01M | 97.48% |
| 2018-09-30 | $15.20M | -62.39% |
| 2018-06-30 | $40.41M | 361.24% |
| 2018-03-31 | $8.76M | -10.58% |
| 2017-12-31 | $9.80M | -13.73% |
| 2017-09-30 | $11.36M | 0.11% |
| 2017-06-30 | $11.35M | 7.97% |
| 2017-03-31 | $10.51M | -53.60% |
| 2016-12-31 | $22.65M | 152.06% |
| 2016-09-30 | $8.98M | 28.76% |
| 2016-06-30 | $6.98M | -77.69% |
| 2016-03-31 | $31.28M | 403.07% |
| 2015-12-31 | $6.22M | 13.47% |
| 2015-09-30 | $5.48M | -58.54% |
| 2015-06-30 | $13.22M | -61.35% |
| 2015-03-31 | $34.20M | 133.68% |
| 2014-12-31 | $14.64M | -56.83% |
| 2014-09-30 | $33.90M | 303.04% |
| 2014-06-30 | $8.41M | - |
| 2014-03-31 | $8.41M | 24.72% |
| 2013-12-31 | $6.74M | 7.59% |
| 2013-09-30 | $6.27M | - |
| 2013-06-30 | $6.27M | - |
| 2013-03-31 | $6.27M | -0.22% |
| 2012-12-31 | $6.28M | 0.22% |
| 2012-09-30 | $6.27M | -0.32% |
| 2012-06-30 | $6.29M | 0.32% |
| 2012-03-31 | $6.27M | - |
Agios Pharmaceuticals generated $8.62M in revenue during Q2 2024, up 5.20% compared to the previous quarter, and up 153.59% compared to the same period a year ago.
Agios Pharmaceuticals Revenue Breakdown
Agios Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| Product | $26.82M | $11.74M | $121.09M | $59.85M | $13.84M |
| Royalty | - | $2.50M | $10.26M | $10.54M | $7.21M |
| Collaboration Revenue, Related Party | - | - | $68.27M | $39.26M | $60.66M |
| Commercialization Activity | - | - | $3.93M | $3.30M | - |
| Committee Participation | - | - | - | - | - |
| Development Activities | - | - | - | - | - |
| Research Services | - | - | $64.35M | $35.95M | - |
| Collaboration Revenue, Other | - | - | - | $8.26M | $12.67M |
Agios Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $8.62M | $8.19M | $7.10M | $7.40M | $6.71M | $5.61M | $4.31M | $3.52M | $3.08M | $832.00K | $39.12M | $31.72M | $27.58M | $22.67M | $19.56M | $9.14M | $9.38M | $4.46M | - | - |
| Royalty | - | - | - | - | - | $2.91M | $683.00K | $3.34M | $3.33M | $2.97M | $2.20M | $2.22M | $2.00M | - | - | - | - | - | - | - |
| Collaboration Revenue, Related Party | - | - | - | - | - | - | - | - | $2.50M | $1.24M | $1.21M | $5.74M | $60.10M | $6.84M | $5.52M | $8.98M | $18.18M | $8.73M | - | - |
| Commercialization Activity | - | - | - | - | - | - | - | - | - | - | $1.02M | $804.00K | $821.00K | $824.00K | - | - | - | - | - | - |
| Research Services | - | - | - | - | - | - | - | - | - | - | $214.00K | $6.04M | - | - | - | - | - | - | - | - |
| Collaboration Revenue, Other | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $6.06M | $970.00K | $230.00K | - | - | - |
| DevelopmentActivitiesMember | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ResearchServicesMember | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $4.70M | $8.15M | - | - | - |
Agios Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Product (100.00%).
Agios Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BMRN | BioMarin Pharmaceutical | $2.42B | $712.03M |
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| KYMR | Kymera Therapeutics | $78.59M | $10.29M |
| ARVN | Arvinas | $78.50M | $76.50M |
| NRIX | Nurix Therapeutics | $76.99M | $12.09M |
| MRSN | Mersana Therapeutics | $36.85M | $2.29M |
| AGIO | Agios Pharmaceuticals | $26.82M | $8.62M |
| RLAY | Relay Therapeutics | $25.55M | - |
| IDYA | IDEAYA Biosciences | $23.39M | - |
| ANAB | AnaptysBio | $17.16M | $10.97M |
| MGTX | MeiraGTx | $14.02M | $282.00K |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| MREO | Mereo BioPharma Group | $10.00M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| PLRX | Pliant Therapeutics | $1.58M | - |
| FIXX | Q32 Bio | $1.16M | - |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| CGEM | Cullinan Oncology | - | - |
| BDTX | Black Diamond Therapeutics | - | - |
| CCCC | C4 Therapeutics | - | - |
| COGT | Cogent Biosciences | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| SNDX | Syndax Pharmaceuticals | - | $3.50M |
| KALV | KalVista Pharmaceuticals | - | - |
AGIO Revenue FAQ
What is Agios Pharmaceuticals’s yearly revenue?
Agios Pharmaceuticals's yearly revenue for 2023 was $26.82M, representing an increase of 88.36% compared to 2022. The company's yearly revenue for 2022 was $14.24M, representing an increase of 100.00% compared to 2021. AGIO's yearly revenue for 2021 was $0, representing a decrease of -100.00% compared to 2020.
What is Agios Pharmaceuticals’s quarterly revenue?
Agios Pharmaceuticals's quarterly revenue for Q2 2024 was $8.62M, a 5.20% increase from the previous quarter (Q1 2024), and a 28.35% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $8.19M, a 15.29% increase from the previous quarter (Q4 2023), and a 46.00% increase year-over-year (Q1 2023). AGIO's quarterly revenue for Q4 2023 was $7.1M, a -4.00% decrease from the previous quarter (Q3 2023), and a 64.80% increase year-over-year (Q4 2022).
What is Agios Pharmaceuticals’s revenue growth rate?
Agios Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was -77.25%.
What are Agios Pharmaceuticals’s revenue streams?
Agios Pharmaceuticals's revenue streams in c 23 are Product
What is Agios Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Agios Pharmaceuticals was Product. This segment made a revenue of $26.82M, representing 100.00% of the company's total revenue.